These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22269804)

  • 1. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.
    Monaghan DT; Irvine MW; Costa BM; Fang G; Jane DE
    Neurochem Int; 2012 Sep; 61(4):581-92. PubMed ID: 22269804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel family of negative and positive allosteric modulators of NMDA receptors.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Skifter DA; Jane DE; Monaghan DT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):614-21. PubMed ID: 20858708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of
    Strong KL; Epplin MP; Ogden KK; Burger PB; Kaiser TM; Wilding TJ; Kusumoto H; Camp CR; Shaulsky G; Bhattacharya S; Perszyk RE; Menaldino DS; McDaniel MJ; Zhang J; Le P; Banke TG; Hansen KB; Huettner JE; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2021 Jan; 12(1):79-98. PubMed ID: 33326224
    [No Abstract]   [Full Text] [Related]  

  • 4. Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
    Burnell ES; Irvine M; Fang G; Sapkota K; Jane DE; Monaghan DT
    J Med Chem; 2019 Jan; 62(1):3-23. PubMed ID: 29446949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792.
    Sapkota K; Burnell ES; Irvine MW; Fang G; Gawande DY; Dravid SM; Jane DE; Monaghan DT
    Neuropharmacology; 2021 Dec; 201():108818. PubMed ID: 34610288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.
    Swanger SA; Vance KM; Acker TM; Zimmerman SS; DiRaddo JO; Myers SJ; Bundgaard C; Mosley CA; Summer SL; Menaldino DS; Jensen HS; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2018 Feb; 9(2):306-319. PubMed ID: 29043770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
    Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
    Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.
    Khatri A; Burger PB; Swanger SA; Hansen KB; Zimmerman S; Karakas E; Liotta DC; Furukawa H; Snyder JP; Traynelis SF
    Mol Pharmacol; 2014 Nov; 86(5):548-60. PubMed ID: 25205677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid.
    Irvine MW; Fang G; Sapkota K; Burnell ES; Volianskis A; Costa BM; Culley G; Collingridge GL; Monaghan DT; Jane DE
    Eur J Med Chem; 2019 Feb; 164():471-498. PubMed ID: 30622023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Dihydropyrrolo[1,2-
    Epplin MP; Mohan A; Harris LD; Zhu Z; Strong KL; Bacsa J; Le P; Menaldino DS; Traynelis SF; Liotta DC
    J Med Chem; 2020 Jul; 63(14):7569-7600. PubMed ID: 32538088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.
    Sapkota K; Dore K; Tang K; Irvine M; Fang G; Burnell ES; Malinow R; Jane DE; Monaghan DT
    Biochem Pharmacol; 2019 Jan; 159():140-153. PubMed ID: 30503374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor.
    Kaiser TM; Kell SA; Kusumoto H; Shaulsky G; Bhattacharya S; Epplin MP; Strong KL; Miller EJ; Cox BD; Menaldino DS; Liotta DC; Traynelis SF; Burger PB
    Mol Pharmacol; 2018 Feb; 93(2):141-156. PubMed ID: 29242355
    [No Abstract]   [Full Text] [Related]  

  • 13. The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors.
    Strong KL; Epplin MP; Bacsa J; Butch CJ; Burger PB; Menaldino DS; Traynelis SF; Liotta DC
    J Med Chem; 2017 Jul; 60(13):5556-5585. PubMed ID: 28586221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptors containing GluN2C and GluN2D subunits have opposing roles in modulating neuronal oscillations; potential mechanism for bidirectional feedback.
    Mao Z; He S; Mesnard C; Synowicki P; Zhang Y; Chung L; Wiesman AI; Wilson TW; Monaghan DT
    Brain Res; 2020 Jan; 1727():146571. PubMed ID: 31786200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of the M1 transmembrane helix and pre-M1 region to positive allosteric modulation and gating of N-methyl-D-aspartate receptors.
    Ogden KK; Traynelis SF
    Mol Pharmacol; 2013 May; 83(5):1045-56. PubMed ID: 23455314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Laube B; Jane DE; Monaghan DT
    Neuropharmacology; 2012 Mar; 62(4):1730-6. PubMed ID: 22155206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
    J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.
    Acker TM; Khatri A; Vance KM; Slabber C; Bacsa J; Snyder JP; Traynelis SF; Liotta DC
    J Med Chem; 2013 Aug; 56(16):6434-56. PubMed ID: 23909910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Glutamate Receptor Subunits Reveal the Transmembrane Domain Is Sufficient for NMDA Receptor Pore Properties but Some Positive Allosteric Modulators Require Additional Domains.
    Wilding TJ; Lopez MN; Huettner JE
    J Neurosci; 2016 Aug; 36(34):8815-25. PubMed ID: 27559165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function.
    Hackos DH; Lupardus PJ; Grand T; Chen Y; Wang TM; Reynen P; Gustafson A; Wallweber HJ; Volgraf M; Sellers BD; Schwarz JB; Paoletti P; Sheng M; Zhou Q; Hanson JE
    Neuron; 2016 Mar; 89(5):983-99. PubMed ID: 26875626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.